Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant
Frontiers in Bioscience-Landmark · 25.07.2024 · 29 (7)
DOI: 10.31083/j.fbl2907272 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 25.07.2024. Verfasst von Wenshu Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Soochow University, Soochow University, 215006 Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhou Basic Research Key Project, Suzhou health youth backbone talent "national tutorial system" training project, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
The p53, a pivotal tumor suppressor, regulates various cellular responses, including DNA repair and apoptosis. Normally, p53 levels are low due to murine double minute clone 2 (MDM2) mediated polyubiquitination. However, stress signals disrupt p53-MDM2 interaction, stabilizing p53 and activating target genes. Dysfunctional p53 is common in cancers, especially colorectal cancer (CRC), with TP53 mutations in 43% of tumors. These mutations impair wild-type p53 function or confer novel activities, promoting cancer progression. Despite drugs targeting p53 entering trials, understanding wild-type and mutant p53 functions is crucial for novel CRC therapies. P53 mutations not only impact DNA repair and apoptosis but also play a crucial role in tumor immunotherapy. While rendering tumors resistant to chemotherapy, p53 mutations provide opportunities for immunotherapy due to neoantigen-rich tumors. Additionally, p53 mutations influence tumor microenvironment cells, such as fibroblasts and immunosuppressive cells, through p53-mediated signaling pathways. Investigating p53 mutations in tumor therapy is vital for personalized medicine and immunotherapy. In cancer treatment research, scientists explore drugs and strategies to restore or enhance p53 function. Targeting wild-type p53 aims to restore DNA repair and cell cycle control, while targeting mutant p53 seeks new drugs to inhibit its detrimental effects, advancing tumor treatment. Understanding p53 drugs and strategies is crucial for cancer therapy progress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital of Soochow University, Soochow University, 215006 Suzhou, Jiangsu, China.
- Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Soochow University, 215006 Suzhou, Jiangsu, China.
Förderung
- Suzhou Basic Research Key Project
- Suzhou health youth backbone talent "national tutorial system" training project
- Beijing Xisike Clinical Oncology Research Foundation
- Suzhou health youth backbone talent “national tutorial system” training project
Zitieren
APA
Li, W., Li, L., Yang, H., Shi, C., Lei, Z., Guo, L., & Wang, Y. (2024). Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant. Frontiers in Bioscience-Landmark, 29(7). https://doi.org/10.31083/j.fbl2907272
Vancouver
Li W, Li L, Yang H, Shi C, Lei Z, Guo L, et al. Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant. Frontiers in Bioscience-Landmark. 2024;29(7). doi:10.31083/j.fbl2907272
BibTeX
@article{Li2024,
author = {Li, Wenshu and Li, Longyuan and Yang, Huan and Shi, Chenxi and Lei, Zhe and Guo, Lingchuan and Wang, Yuhong},
title = {Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
volume = {29},
number = {7},
doi = {10.31083/j.fbl2907272}
}
EUVIMED